Welcome to our dedicated page for U S Physical Therapy SEC filings (Ticker: USPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how clinic visit volumes, payer mix, and therapist partnership incentives shape U.S. Physical Therapy’s cash flow can feel overwhelming. When reimbursement tables are buried deep inside a 300-page report, even seasoned analysts struggle to find answers—especially if they just want U.S. Physical Therapy SEC filings explained simply.
StockTitan solves that problem. Our AI reads every U.S. Physical Therapy annual report 10-K simplified, flags changes in segment margins inside each U.S. Physical Therapy quarterly earnings report 10-Q filing, and streams U.S. Physical Therapy Form 4 insider transactions real-time. Need context on an unexpected acquisition? We surface the corresponding U.S. Physical Therapy 8-K material events explained alongside plain-English summaries. Prefer raw numbers? Download exhibits without digging through EDGAR.
- Instant alerts for U.S. Physical Therapy insider trading Form 4 transactions
- Side-by-side comparison of clinic metrics across quarters—perfect for U.S. Physical Therapy earnings report filing analysis
- Highlights of salary, bonus, and option grants pulled from the latest U.S. Physical Therapy proxy statement executive compensation
- Contextual pop-ups that make understanding U.S. Physical Therapy SEC documents with AI effortless
Whether you’re monitoring U.S. Physical Therapy executive stock transactions Form 4 before a new clinic rollout or checking covenant compliance after a debt refinancing, our real-time feed and AI-powered summaries give you the insight you need—without wading through endless footnotes.
Reeve Graham D., Chief Operating Officer of U S Physical Therapy, Inc. (USPH), reported an insider sale on 08/11/2025. The Form 4 discloses a disposition of 1,792 shares of common stock at a price of $86.57 per share. Following the sale, the filing shows 22,246 shares beneficially owned directly and 1,808 shares held indirectly through the Reeve Trust.
The filing also details that 17,244 shares are restricted stock granted under the companys 2003 Stock Incentive Plan, with a specified vesting schedule listing dates and tranche sizes through March 6, 2029, conditional on continued employment.
U.S. Physical Therapy, Inc. (NYSE: USPH) reported a Regulation FD disclosure in a Form 8-K stating that on August 12, 2025 the company updated its investor presentation. The presentation provides an overview of the company and is posted on the company website under Investor Relations.
The filing identifies Exhibit 99.1 as the "USPH Investor's Presentation for the Three and Six months Ended June 30, 2025." The company expressly states the information is furnished, not filed, and therefore is not subject to Section 18 liabilities or automatically incorporated by reference into registration statements.
US Physical Therapy (USPH) reported a proposed sale of 1,792 shares of Class A common stock on the NYSE through J.P. Morgan Securities, with an aggregate market value of $155,124.48. The filing states the shares were acquired on 05/20/2025 by vesting of restricted stock grants (grants issued from 08/16/2021 to 02/24/2025) and lists an approximate sale date of 08/11/2025 with payment in cash.
Against total outstanding shares of 15,190,000, the 1,792-share notice represents about 0.0118% of the company’s shares outstanding. The filer reported no securities sold in the past three months. The form includes the required compliance representation under Rule 144 and identifies J.P. Morgan Securities LLC as the broker.
U.S. Physical Therapy, Inc. (NYSE: USPH) hosted a conference call and webcast on August 7, 2025 to discuss results for the three and six months ended June 30, 2025. The company furnished the conference call transcript as Exhibit 99.1 to this Current Report and stated the materials are furnished, not filed, so they are not subject to Section 18 liabilities and are not incorporated by reference unless expressly provided.
This 8-K itself does not present financial statements or earnings figures; it makes management commentary and the call transcript available to investors as a supplemental disclosure.
Q2 2025 performance (USPH)
- Net revenue rose 18% YoY to $197.3 m; six-month revenue $381.1 m (+18%).
- Net income attributable to shareholders jumped 65% to $12.4 m; diluted EPS $0.58 versus $0.47.
- Operating income improved 60% to $24.9 m; margin expanded to 12.6% (9.3% LY) aided by a $0.8 m gain on contingent earn-out revaluation.
- Gross margin inched up to 21.1% from 20.3% despite higher salary and rent expense.
- Cash from operations YTD $30.2 m (-10%); cash balance fell to $34.1 m after $6.9 m of acquisitions and $13.7 m in dividends.
- Debt profile: revolver borrowings increased to $24.5 m (11.0 m YE); term loan reduced to $127.1 m. Interest expense up 22% YoY.
- Clinic count reached 768 (+46 YoY) after 6 openings, 4 closures and two bolt-on deals (3 clinics + home-care business).
- Equity climbed to $500.8 m; quarterly dividend lifted to $0.45.
Other notes: No impairment triggers were identified. New U.S. tax legislation signed 4 Jul 25 is not yet reflected. Management continues acquisitive growth strategy.
FAQ
What is the current stock price of U S Physical Therapy (USPH)?
What is the market cap of U S Physical Therapy (USPH)?
